Developing and Researching Innovative Strategies
IDENTIFYING SOLUTIONS
EMERVAX - “emerging vaccines against emerging viruses”, founded in 2021, is developing vaccines against emerging viral infections with the potential to cause epidemics or pandemics similar to COVID-19.
The vaccines will be critical for:
Populations in endemic areas.
General populations during epidemics and pandemics.
Individuals with potential exposure (e.g., healthcare workers, travelers).
U.S. military deployed around the globe.
The U.S. Strategic National Stockpile for Public Health Emergency.
The scientific founders are pioneers in emerging viruses and RNA biology, and EMERVAX arose from work they carried out while at the University of Texas Medical Branch (UTMB) and the Galveston National Laboratory in Galveston, Texas.
EMERVAX mRNA vaccines will target emerging RNA viruses. RNA viruses have caused the most severe pandemics of the last 100 years – influenza, AIDS, dengue, and COVID-19 are salient examples. EMERVAX will anticipate the next pandemic by creating vaccines for emerging RNA viruses with high epidemic potential.